Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for a range of metabolic and endocrine disorders. The company's pipeline is anchored by VK2809, an orally administered selective agonist of the thyroid hormone receptor beta (TRß). This promising candidate is currently undergoing Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Viking is also advancing VK5211, an oral, non-steroidal selective androgen receptor modulator, through Phase II trials for patients recovering from hip fracture surgery. Further pipeline assets include VK0612, being evaluated in Phase II for metabolic disorders and anemia, and VK2735, a novel dual agonist of glucagon-like peptide 1, which has entered Phase 1 clinical trials. Additionally, VK0214, another TRß agonist, is being developed for X-linked adrenoleukodystrophy. Viking's strategic focus lies in leveraging its expertise in small molecule drug development to address significant unmet medical needs in areas with substantial patient populations and limited therapeutic options, positioning itself as a key player in the biopharmaceutical landscape.